These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22414602)

  • 21. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
    Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
    Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
    Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
    Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
    Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
    Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma.
    Huang PS; Chung IH; Lin YH; Lin TK; Chen WJ; Lin KH
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29758012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
    Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
    Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
    Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
    J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA and ALK-positive anaplastic large cell lymphoma.
    Hoareau-Aveilla C; Merkel O; Meggetto F
    Front Biosci (Schol Ed); 2015 Jun; 7(2):217-25. PubMed ID: 25961697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
    Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
    Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis.
    Zhang Q; Wang HY; Bhutani G; Liu X; Paessler M; Tobias JW; Baldwin D; Swaminathan K; Milone MC; Wasik MA
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15843-8. PubMed ID: 19717436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
    Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
    Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
    Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
    Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).
    Zhang JG; Wang JJ; Zhao F; Liu Q; Jiang K; Yang GH
    Clin Chim Acta; 2010 Jun; 411(11-12):846-52. PubMed ID: 20223231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
    Wang YW; Tu PH; Lin KT; Lin SC; Ko JY; Jou YS
    Neoplasia; 2011 Aug; 13(8):704-15. PubMed ID: 21847362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
    Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
    Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study.
    Chen TD; Chang IC; Liu HP; Wu YC; Wang CL; Chen YT; Chen YR; Huang SF
    Chang Gung Med J; 2012; 35(4):309-17. PubMed ID: 22913857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.